Y Forslin1,2, J Martola3,2, Å Bergendal3, S Fredrikson3,4, M K Wiberg3,2,5, T Granberg3,2. 1. From the Department of Clinical Neuroscience (Y.F., J.M., Å.B., S.F., M.K.W., T.G.), Karolinska Institutet, Stockholm, Sweden yngve.forslin@ki.se. 2. Departments of Radiology (Y.F., J.M., M.K.W., T.G.). 3. From the Department of Clinical Neuroscience (Y.F., J.M., Å.B., S.F., M.K.W., T.G.), Karolinska Institutet, Stockholm, Sweden. 4. Neurology (S.F.), Karolinska University Hospital, Stockholm, Sweden. 5. Department of Medical and Health Sciences (M.K.W.), Division of Radiological Sciences, Linköping University, Linköping, Sweden.
Abstract
BACKGROUND AND PURPOSE: Brain gadolinium retention is consistently reported for linear gadolinium-based contrast agents, while the results for macrocyclics are contradictory and potential clinical manifestations remain controversial. Furthermore, most previous studies are based on conventional T1-weighted MR imaging. We therefore aimed to quantitatively investigate longitudinal and transversal relaxation in the brain in relation to previous gadolinium-based contrast agent administration and explore associations with disability in multiple sclerosis. MATERIALS AND METHODS: Eighty-five patients with MS and 21 healthy controls underwent longitudinal and transverse relaxation rate (R1 and R2) relaxometry. Patients were divided into linear, mixed, and macrocyclic groups based on previous gadolinium-based contrast agent administration. Neuropsychological testing was performed in 53 patients. The dentate nucleus, globus pallidus, caudate nucleus, and thalamus were manually segmented. Repeatability measures were also performed. RESULTS: The relaxometry was robust (2.0% scan-rescan difference) and detected higher R1 (dentate nucleus, globus pallidus, caudate nucleus, thalamus) and R2 (globus pallidus, caudate nucleus) in patients receiving linear gadolinium-based contrast agents compared with controls. The number of linear gadolinium-based contrast agent administrations was associated with higher R1 and R2 in all regions (except R2 in the thalamus). No similar differences and associations were found for the macrocyclic group. Higher relaxation was associated with lower information-processing speed (dentate nucleus, thalamus) and verbal fluency (caudate nucleus, thalamus). No associations were found with physical disability or fatigue. CONCLUSIONS: Previous linear, but not macrocyclic, gadolinium-based contrast agent administration is associated with higher relaxation rates in a dose-dependent manner. Higher relaxation in some regions is associated with cognitive impairment but not physical disability or fatigue in MS. The findings should be interpreted with care but encourage studies into gadolinium retention and cognition.
BACKGROUND AND PURPOSE: Brain gadolinium retention is consistently reported for linear gadolinium-based contrast agents, while the results for macrocyclics are contradictory and potential clinical manifestations remain controversial. Furthermore, most previous studies are based on conventional T1-weighted MR imaging. We therefore aimed to quantitatively investigate longitudinal and transversal relaxation in the brain in relation to previous gadolinium-based contrast agent administration and explore associations with disability in multiple sclerosis. MATERIALS AND METHODS: Eighty-five patients with MS and 21 healthy controls underwent longitudinal and transverse relaxation rate (R1 and R2) relaxometry. Patients were divided into linear, mixed, and macrocyclic groups based on previous gadolinium-based contrast agent administration. Neuropsychological testing was performed in 53 patients. The dentate nucleus, globus pallidus, caudate nucleus, and thalamus were manually segmented. Repeatability measures were also performed. RESULTS: The relaxometry was robust (2.0% scan-rescan difference) and detected higher R1 (dentate nucleus, globus pallidus, caudate nucleus, thalamus) and R2 (globus pallidus, caudate nucleus) in patients receiving linear gadolinium-based contrast agents compared with controls. The number of linear gadolinium-based contrast agent administrations was associated with higher R1 and R2 in all regions (except R2 in the thalamus). No similar differences and associations were found for the macrocyclic group. Higher relaxation was associated with lower information-processing speed (dentate nucleus, thalamus) and verbal fluency (caudate nucleus, thalamus). No associations were found with physical disability or fatigue. CONCLUSIONS: Previous linear, but not macrocyclic, gadolinium-based contrast agent administration is associated with higher relaxation rates in a dose-dependent manner. Higher relaxation in some regions is associated with cognitive impairment but not physical disability or fatigue in MS. The findings should be interpreted with care but encourage studies into gadolinium retention and cognition.
Authors: Robert J McDonald; Jennifer S McDonald; David F Kallmes; Mark E Jentoft; David L Murray; Kent R Thielen; Eric E Williamson; Laurence J Eckel Journal: Radiology Date: 2015-03-05 Impact factor: 11.105
Authors: Maria Camilla Rossi Espagnet; Bruno Bernardi; Luca Pasquini; Lorenzo Figà-Talamanca; Paolo Tomà; Antonio Napolitano Journal: Pediatr Radiol Date: 2017-05-19
Authors: Luca Roccatagliata; Luisa Vuolo; Laura Bonzano; Anna Pichiecchio; Giovanni Luigi Mancardi Journal: Radiology Date: 2009-05 Impact factor: 11.105
Authors: Carlo A Mallio; Claudia Piervincenzi; Eliana Gianolio; Vincenzo Cirimele; Luigi G Papparella; Massimo Marano; Livia Quintiliani; Silvio Aime; Filippo Carducci; Paul M Parizel; Carlo C Quattrocchi Journal: J Magn Reson Imaging Date: 2019-01-25 Impact factor: 4.813
Authors: Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith Journal: Neuroimage Date: 2011-09-16 Impact factor: 6.556
Authors: M Vågberg; M Axelsson; R Birgander; J Burman; C Cananau; Y Forslin; T Granberg; M Gunnarsson; A von Heijne; L Jönsson; V D Karrenbauer; E-M Larsson; T Lindqvist; J Lycke; L Lönn; E Mentesidou; S Müller; P Nilsson; F Piehl; A Svenningsson; M Vrethem; J Wikström Journal: Acta Neurol Scand Date: 2016-08-24 Impact factor: 3.209
Authors: Elke Anklam; Martin Iain Bahl; Robert Ball; Richard D Beger; Jonathan Cohen; Suzanne Fitzpatrick; Philippe Girard; Blanka Halamoda-Kenzaoui; Denise Hinton; Akihiko Hirose; Arnd Hoeveler; Masamitsu Honma; Marta Hugas; Seichi Ishida; George En Kass; Hajime Kojima; Ira Krefting; Serguei Liachenko; Yan Liu; Shane Masters; Uwe Marx; Timothy McCarthy; Tim Mercer; Anil Patri; Carmen Pelaez; Munir Pirmohamed; Stefan Platz; Alexandre Js Ribeiro; Joseph V Rodricks; Ivan Rusyn; Reza M Salek; Reinhilde Schoonjans; Primal Silva; Clive N Svendsen; Susan Sumner; Kyung Sung; Danilo Tagle; Li Tong; Weida Tong; Janny van den Eijnden-van-Raaij; Neil Vary; Tao Wang; John Waterton; May Wang; Hairuo Wen; David Wishart; Yinyin Yuan; William Slikker Journal: Exp Biol Med (Maywood) Date: 2021-11-16
Authors: Christian Thaler; Anna A Kyselyova; Tobias D Faizy; Marie T Nawka; Sune Jespersen; Brian Hansen; Jan-Patrick Stellmann; Christoph Heesen; Klarissa H Stürner; Maria Stark; Jens Fiehler; Maxim Bester; Susanne Gellißen Journal: PLoS One Date: 2021-02-04 Impact factor: 3.240
Authors: A Dal-Bianco; R Schranzer; G Grabner; M Lanzinger; S Kolbrink; G Pusswald; P Altmann; M Ponleitner; M Weber; B Kornek; K Zebenholzer; C Schmied; T Berger; H Lassmann; S Trattnig; S Hametner; F Leutmezer; P Rommer Journal: Front Neurol Date: 2021-12-21 Impact factor: 4.003